Message 002
Communication from the Commission - TRIS/(2018) 02087
Directive (EU) 2015/1535
Translation of the message 001
Notification: 2018/0381/LT
No abre el plazo - Nezahajuje odklady - Fristerne indledes ikke - Kein Fristbeginn - Viivituste perioodi ei avata - Καμμία έναρξη προθεσμίας - Does not open the delays - N'ouvre pas de délais - Non fa decorrere la mora - Neietekmē atlikšanu - Atidėjimai nepradedami - Nem nyitja meg a késéseket - Ma’ jiftaħx il-perijodi ta’ dawmien - Geen termijnbegin - Nie otwiera opóźnień - Não inicia o prazo - Neotvorí oneskorenia - Ne uvaja zamud - Määräaika ei ala tästä - Inleder ingen frist - Не се предвижда период на прекъсване - Nu deschide perioadele de stagnare - Nu deschide perioadele de stagnare.
(MSG: 201802087.EN)
1. MSG 002 IND 2018 0381 LT EN 26-07-2018 LT NOTIF
2. LT
3A. Lietuvos standartizacijos departamentas
Algirdo g. 31, LT- 03219 Vilnius
Tel. +370 (5) 270 9358
Elektroninis paštas dir9834@lsd.lt
3B. Lietuvos Respublikos sveikatos apsaugos ministerija
Vilniaus g. 33, LT- 01506 Vilnius
Tel. +370 (5) 266 14 02, faks. +370 (5) 266 14 02
Elektroninis paštas ministerija@sam.lt
4. 2018/0381/LT - C00C
5. Draft order of the Minister for Health of the Republic of Lithuania on the amendment of Order No 5 of the Minister for Health of the Republic of Lithuania of 6 January 2000 adopting the lists of narcotic drugs and psychotropic substances
6. In accordance with the provisions of Law No XIII-1161 of the Republic of Lithuania amending Articles 1, 2, 3, 4 and103, renumbering and amending Article 211 of Law No VIII-602 on the control of narcotic drugs and psychotropic substances, and adding to Article 61and Section 41 (hereinafter 'Law No XIII-1161') adopted by the Seimas (Lithuanian Parliament) of the Republic of Lithuania on 17 May 2018, market restriction measures shall be introduced regarding two chemical substances along with the proposal to include them in the newly approved List IV of narcotic drugs and psychotropic substances. The draft proposes including 1,4–Butanediol (1,4–BD) and gamma-Butyrolactone (GBL) in List IV.
7. -
8. Law No XIII-1161 of the Republic of Lithuania amending Articles 1, 2, 3, 4 and 103, renumbering and amending Article 211 of Law No VIII-602 on the control of narcotic drugs and psychotropic substances, and adding to the Article 61 and Section 41 established List IV for narcotic drugs and psychotropic substances which is to include narcotic drugs and psychotropic substances that may be used for healthcare purposes and/or for the purposes of industry not related to pharmaceutical products, but that are hazardous to human health due to their harmful effects when abused. The draft order of the Minister for Health of the Republic of Lithuania on the amendment of Order No 5 of the Minister for Health of the Republic of Lithuania of 6 January 2000 adopting the lists of narcotic drugs and psychotropic substances proposes including such substances as gamma-Butyrolactone (GBL) and 1,4–Butanediol (1,4 BD) in List IV entitled 'Narcotic drugs and psychotropic substances permitted for use for medical purposes and/or for industrial purposes not related to pharmaceutical products' which is currently being drawn up. These substances are used in the chemical industry but also abused for intoxication purposes. Lithuania has become a transit country for these substances owing to the fact that, as of yet, there have been no market restriction measures introduced for them. Including GBL and 1,4 BD in List IV of controlled narcotic drugs and psychotropic substances would mean activities involving these substances would only be authorised for those legal entities which have obtained a permit from the Drug, Tobacco and Alcohol Control Department for activities with List IV substances in line with the requirements of the Law on the control of narcotic drugs and psychotropic substances.
9. Until now, Lithuania has not applied any restrictions for placing certain substances on the market, e.g. gamma-Butyrolactone (GBL) and 1,4-Butanediol (1,4 BD). Measures to regulate activities involving such chemical substances and their placement on the market are not sufficient to ensure that they are not used for intoxication. These substances are monitored as substances used for intoxication and causing serious health problems. A report by the European Monitoring Centre for Drugs and Drug Addiction states that GBL is ranked fourth among 10 psychoactive substances that resulted in cases of serious poisoning and which required emergency hospital treatment. The report also states that the number of poisoning cases associated with GBL has increased. According to available information, 80 000 kg of GBL were shipped in small consignments from Lithuania in 2016. It should be noted that GBL is being acquired mostly by natural persons who are likely to use this substance for intoxication and distribute it to other users.
10. To restrict the sale or use of chemical substances, preparations or products
Reference(s) to basic text(s): https://e-seimas.lrs.lt/portal/legalAct/lt/TAP/76d3462185c111e8aa33fe8f0fea665f?positionInSearchResults=5&searchModelUUID=2c274de1-9b6f-498a-93f4-8b3383d79fdc
https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/b45712825e5011e896f6c1bcca8cd3a8?positionInSearchResults=0&searchModelUUID=c63044c3-15be-4394-b29c-e4c1af95b4d1
11. No
12. -
13. No
14. No
15. -
16. TBT aspect
No - the draft is neither a technical regulation nor a conformity assessment procedure.
No - the draft has no significant impact on international trade.
SPS aspect
No - the draft has no significant impact on international trade.
No - the draft is neither a sanitary nor phytosanitary measure.
**********
European Commission
Contact point Directive (EU) 2015/1535
Fax: +32 229 98043
email: grow-dir2015-1535-central@ec.europa.eu
